Evaluation of correlation between CD44, radiotherapy response, and survival rate in patients with advanced stage of head and neck squamous cell carcinoma (HNSCC)

Parul Dubey¹ | Rajeev Gupta¹ | Anupam Mishra² | Vijay Kumar³ | Smrati Bhadauria⁴ | Madan Lal Brahma Bhatt¹

¹Department of Radiotherapy, King George's Medical University, Lucknow, India
²Department of Otorhinolaryngology & Head Neck Surgery, King George's Medical University, Lucknow, India
³Department of Surgical Oncology, King George's Medical University, Lucknow, India
⁴Division of Toxicology & Experimental Medicine, Central Drug Research Institute (CSIR), Lucknow, India

Correspondence
Madan Lal Brahma Bhatt, Department of Radiotherapy, King George's Medical University, Lucknow, Uttar Pradesh 226003, India.
Emails: bhattmlb2907@gmail.com; drmblbhatt@yahoo.com

Abstract

Purpose: Cancer stem cells (CSCs) constitute a distinctive subpopulation of cancer cells that are competent in tumor initiation, invasion, recurrence, and resistance to chemoradiotherapy. CD44, a hyaluronic acid (HA) receptor has been considered as a potential CSC marker in head and neck cancer. The purpose of this study is to evaluate the correlation between CD44 and clinicopathological parameters, treatment response, survival, and recurrence.

Methods: The CD44 expression was examined by immunohistochemistry (IHC) in 90 samples of head and neck squamous cell carcinoma (HNSCC) confirmed patients. The expression of CD44 and its association with clinicopathological parameters, treatment response, and survival was determined.

Results: In all HNSCC patient samples, CD44 was expressed consistently at different intensities. Tumor size ($p < 0.001$), stage ($p < 0.001$), and treatment response ($p < 0.001$) showed statistically significant association with CD44 expression. Alcohol and CD44 were observed as independent predictors of response to radiotherapy using multivariate ordinal logistic regression analysis. Analysis of 2-year overall survival (OS) showed that CD44 expression ($p = 0.02$), tumor size ($p = 0.001$), lymph node status ($p < 0.001$), stage ($p < 0.001$), and grade ($p = 0.007$) were significantly associated with OS. Using Cox regression analysis, lymph node status ($p = 0.001$), grade ($p < 0.001$), recurrence ($p < 0.001$), and CD44 expression ($p = 0.003$) were found to be potential independent predictors of OS.

Conclusion: Our findings suggest that CD44 contributes to resistance to radiotherapy and poor OS. The results also suggest that except for CD44 there could be other factors such as lymph node metastasis, grade, and alcohol which should be investigated as potential targets for therapy.

Keywords

cancer stem cells, CD44, head and neck squamous cell carcinoma, radiotherapy response, survival
1 | INTRODUCTION

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide affecting over 400,000 patients annually leading to over 200,000 deaths. Although advent of newer surgical and endoscopic techniques over last 30–40 years has improved the quality of life, however, the 5-year survival rate has still remained same as earlier (40%–50%). Despite the treatments such as surgery and/or combination of chemotherapy and radiotherapy, the prognosis of HNSCC remains poor due to late stage diagnosis, high rates of primary site recurrence, and common metastasis to locoregional lymph nodes. In case of HNSCC, patients with HPV-positive disease exhibited better prognosis. Especially in case of oropharynx cancer, HPV infection was considered as the major causative agent. In United States, it accounts for approximately 60%–70% of oropharynx cancer. Within Western Europe, the prevalence varies ranging between 6.1% and 75%. However, in third world countries, HPV (+) HNSCC is relatively rare with a <10% prevalence. Novel approaches toward increasing the overall survival and disease-free survival as well as improved prognosis/patient outcome are much needed.

Cancer stem cells (CSCs) were first found in leukemia, and since then their presence has been confirmed in various other malignancies. It has been postulated that CSCs play a significant role in the pathobiology of HNSCC. CSCs are cancer cells having capacity for self-renewal, differentiation, and regeneration. Recent studies have demonstrated that CSCs are found within the tumor and are resistant to current treatment modalities leading to relapse. Therefore, CSCs could be the potential therapeutic targets for the better treatment of HNSCC patients.

HNSCCs have heterogeneous cellular composition. Various putative CSC markers reported to be present in HNSCC cell lines are ALDH, CD133, CD44, and others. CD44 was one of the very first CSC markers to be identified in HNSCC. CD44 is a type I transmembrane glycoprotein, receptor for hyaluronic acid and functions as a major adhesion molecule. It is involved in aggregation, proliferation, migration, and angiogenesis. Adhesion to components of the extracellular matrix is influenced by the interaction between hyaluronic acid and CD44. It has been reported that high levels of BMI-1 gene were expressed in CD44+ cells and its role has been found in self-renewal and tumorigenesis.

Various cell line-based studies have substantiated the presence of CSCs as one of the critical determinants of response/relapse of cancer cells to radiotherapy. However, definitive clinical investigations for assessing predictive significance of CSCs with reference to radiotherapy are lacking. In view of this, current study was planned to evaluate the expression of CSC marker “CD44” in relation to the clinicopathological features of HNSCC patients vis-a-vis their response to radiotherapy. Predictive significance of CD44 was assessed in determining response/relapse of HNSCC patients to radiotherapy as well as clinical outcome and overall survival (OS).

2 | MATERIALS AND METHODS

2.1 | Study population

From March 2016 to March 2017, total 90 histopathologically confirmed patients for head and neck squamous cell carcinoma (HNSCC) were recruited in this study for the evaluation of cancer stem cell marker “CD44” by immunohistochemistry (IHC). All inoperable and non-metastatic patients strongly recommended only for chemoradiotherapy treatment were included in the study. Patients with HPV infection, prior history of chemoradiotherapy or surgery, and distant metastasis were excluded from the study. Patients having habits of consuming tobacco and alcohol were included in the study. Patients consuming alcohol are categorized into three categories: (1) former drinker, (2) occasional drinker (consumed alcohol once in a week), and (3) heavy drinkers (consumed alcohol daily). These patients underwent biopsy. Healthy matched individuals (n = 90) served as control group.

2.2 | Treatment and response assessment

HNSCC patients were treated with standard treatment of radiotherapy. Radiotherapy was performed using linear accelerator. For 7 weeks, a dose of 70 Gy/35 fractions, 5 Fc/week of radiation was delivered (46 Gy/23# to primary tumor and whole neck followed by 24 Gy/12# to tumor and neck sparing the cord). For 7 weeks, 30 mg/m² dose of cisplatin with a ceiling of absolute dose of 50 mg i.v. weekly was given to fit and adult patients. All patients had received concurrent chemoradiotherapy and cisplatin was given to all the patients. On the basis of 30 mg/m² cisplatin dose, all patients had received 210 mg/m² total dose of cisplatin for 7 weeks. Response was seen after 1 month of completion of treatment. The characteristics of HNSCC patients which includes age, clinical stage, TNM...
classification (defined by the American Joint Committee on Cancer, AJCC 2010, VII Edition)\textsuperscript{15}, and oral habits (Tobacco and alcohol intake) were assessed by radiation oncologist. Assessment of tumor response was performed by standard clinical examination and radiological investigation. The treatment response was stratified on the basis of guidelines defined by Response Evaluation Criteria in Solid Tumors (RECIST) which is a tumor-centric set of published rules that define whether the tumor regresses (responsive), stay the same (stabilize) or worsen (progress) during the treatment. The response criteria included complete response (CR), that is, disappearance of all target lesions and reduction of tumor in short axis to <10 mm; partial response (PR), that is, reduction of at least 30% in the diameter of target lesion and no response (NR) [stable disease (SD) + progressive disease (PD)]. Progressive disease, that is, increase by at least 20% of diameter of target lesion or emergence of one or more new lesions; stable disease, that is, inadequate shrinkage of tumor which meet the requirements for PR or inadequate increase in the size of tumor which meet the requirements for PD.\textsuperscript{20}

After treatment, patients were followed up and evaluated for survival. Treatment response and overall survival (OS) starting from the date of diagnosis to the date of death were considered as the primary endpoints. After the treatment and evaluation, response to radiotherapy was correlated with CD44 expression to find out the role of CSCs as a predictive biomarker of radiotherapy response.

2.3 | Immunohistochemistry

Immunohistochemical detection of CSC marker, CD44 also known as HCAM was performed on a formalin-fixed, paraffin-embedded tissue sections (5 µm). HNSCC tissue slides were deparaffinized, rehydrated, and washed. Endogenous peroxidases were blocked using 0.1% hydrogen peroxide for 15 min at room temperature. Prior to this heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0) was performed for 30 min. The deparaffini- zed and rehydrated tissue sections were incubated overnight with the primary antibody, viz., anti-CD44 mouse monoclonal antibody (HCAM [DF-1485]; sc-7297 Santa Cruz Biotechnology), at 1:50 dilution. Thereafter, samples were incubated for 1 h with HRP-conjugated goat anti-mouse IgG secondary antibody at 1:200 dilution. Antigen was visualized with DAB Peroxidase Substrate (Thermo Fisher Scientific). Finally, tissue specimens were stained with hematoxylin (Thermo Fisher Scientific) to discriminate nucleus from cytoplasm. Thereafter, sections were mounted in DPX (Sigma) and analyzed at 40X magnification using Leica DCF450C bright field/fluorescence microscope. At least two different sections per sample were analyzed. Whole tissue section was evaluated and 10 different fields per section were observed for positive staining. It was grouped as following: no staining (0%), low staining (≤50%), and high staining (>50%).\textsuperscript{21}

2.4 | Statistical analysis

Continuous data were summarized as mean ± SE while discrete (categorical) in number (n) and percentage (%). Continuous groups were compared by independent Student’s \( t \)-test. Categorical groups were compared by the chi-squared (\( \chi^2 \)) test. Univariate and multivariate ordinal logistic regression analyses were performed to assess independent predictor(s) of responsiveness to radiotherapy. Survival analysis was performed using the Kaplan–Meier method and difference between groups was performed by the log-rank test. A two-tailed (\( \alpha = 2 \)) \( p < 0.05 \) was considered statistically significant. Analysis was performed on GraphPad Prism 5.01 and IBM SPSS Statistics 20 software.

3 | RESULTS

3.1 | Basic characteristics of HNSCC patients

The basic characteristics (demographic, clinicopathological, and treatment response) of HNSCC patients are summarized in Table 1. The mean age (±SE) of patients was 46.64 ± 1.19 years and median was 45 years. Most of the patients were of age \( \leq 45 \) years (54.4%) and majority were males (86.7%). Among all the 90 patients, patients who consumed tobacco in any form were 76.7%, and patients who consumed alcohol were 41.1%.

Buccal mucosa 20 (22.2%) was the primary tumor site in majority of the patients (Suppl 1). Furthermore, on considering clinicopathological parameters it was observed that patients were mostly having T4 tumor size (45.5%), N1 lymph node (47.8%), IV stage (61.1%), and moderately differentiated (MD) grade (48.9%).

On taking treatment response into account, 19 (21.1%) patients had complete response (CR), 20 (22.2%) patients had partial response (PR), and 51 (56.7%) patients had no response (NR). Therefore, the overall response (CR + PR) was 43.3%.

3.2 | Assessment of molecular marker expression

The expression of molecular marker CD44 was observed by immunohistochemistry as shown in Figure 1A,B.
CD44 marker was positively expressed in all the patients. However, 17 (18.9%) patients showed low expression and 73 (81.1%) patients had high expression. Majority of tumor specimens showing CD44 expression were collected from oral cavity and relatively smaller numbers were collected from other sites like larynx (n = 6), pharynx (n = 7), and nasal cavity (n = 3) (Suppl 2). No staining (0%) for CD44 was observed in control tissue specimens. Immunohistochemical detection of CD44 specimens in HNSCC patients revealed that at cellular periphery CD44 was predominantly localized. Localization of CD44 was also observed prominently at the invasive front in all HNSCC specimens.

### 3.3 Association of treatment response with demographic, clinicopathological parameters, and molecular marker expression

An association was established between treatment response and various variables (demographic, clinicopathological parameters) which is summarized in Table 2. The significant association was observed between treatment response and alcohol ($\chi^2 = 6.48$, $p = 0.039$), tumor size ($\chi^2 = 13.26$, $p = 0.039$), and stage ($\chi^2 = 8.85$, $p = 0.012$). Significant association between treatment response and CD44 expression ($\chi^2 = 17.21$, $p < 0.001$) was observed which is presented in Figure 1C. These significant associations suggest that these variables could serve as the predictors of responsiveness.

Since among all the demographic and clinicopathological variables only alcohol, tumor size, and stage showed the significant association, we next tried to establish an association of CD44 expression with all the above mentioned variables and it is presented in Figure 1C.

Tumor size ($\chi^2 = 13.41$, $p < 0.0002$) and stage ($\chi^2 = 32.94$, $p < 0.001$) showed highly significant association with CD44 expression. On the other hand, alcohol ($\chi^2 = 0.29$, $p = 0.588$) was not found to be significantly associated with CD44 expression.

### 3.4 Predictors of radiotherapy response

The predictor(s) of response (CR, PR, and NR) to radiotherapy in HNSCC patients were determined by examining the patient’s demographic, clinicopathological characteristics, and CD44 expression using univariate and multivariate ordinal logistic regression analyses. It was considered that responsiveness is the dependent variable and demographic, clinicopathological, and CD44 expression are the independent variables and it are summarized in Table 3.

In univariate ordinal logistic regression analysis, alcohol, stage, and CD44 expression were found to be significantly associated with responsiveness.
Furthermore, when these significant predictors were subjected to multivariate analysis, alcohol and CD44 expression showed significant association with responsiveness. It indicates that alcohol and CD44 expression are independent predictors of responsiveness to radiotherapy in HNSCC patients.

### 3.5 Overall survival of HNSCC patients and its association with clinicopathological characteristics, biomarker expression, and treatment response

The HNSCC patients were followed up for 2 years after treatment. During this period 20 patients (22.2%) died due to disease, 53 (58.9%) patients remained alive while 17 (18.9%) patients were lost to follow-up (LOF). All together this account for total 70 alive (alive + LOF) patients, that is, 77.8% was the incidence of OS. Further during the follow-up, it was observed that 37 (41.1%) patients out of 90 patients showed recurrence.

Analysis of 2-year OS of HNSCC patients with clinicopathological parameters, CD44 expression, and treatment response was performed using the Kaplan–Meier method. The difference between the groups was performed using the log-rank (Mantel–Cox) test and it is summarized graphically in Figure 2. With OS, all clinicopathological characteristics and biomarker expression were found to be significantly ($p < 0.05$ or $p < 0.01$ or $p < 0.001$) associated in our analysis using the log-rank (Mantel–Cox) test. The log-rank test showed that mean survival decreases as the tumor size ($\chi^2 = 16.34$, $p = 0.001$), lymph node ($\chi^2 = 20.57$, $p < 0.001$), stage ($\chi^2 = 14.03$, $p = 0.0002$), and grade ($\chi^2 = 9.84$, $p = 0.007$) increases. In addition to this, it was observed that mean survival also decreases with high expression of CD44 ($\chi^2 = 5.93$, $p = 0.02$) as compared to low expression of CD44. Moreover, our analysis showed that treatment response, that is, CR, PR, and NR were not associated significantly with OS ($\chi^2 = 3.83$, $p = 0.147$).

### 3.6 Independent predictors of survival

Univariate and multivariate Cox regression analyses were performed to determine the independent predictors of time-dependent survival (death and live + LOF). Cox regression analysis was performed between survival and different predictor variables (demographic, clinicopathological, molecular marker expression, treatment response, and recurrence) which are summarized in Table 4.

In univariate analysis, only grade showed the significant association with the survival. However, in multivariate analysis, lymph node, grade, CD44 expression,
and recurrence showed significant association with the survival. Hence, it could be inferred that after adjusting the variables lymph node, grade, CD44 expression, and recurrence could serve as the independent predictors of survival.

4 | DISCUSSION

Cancer stem cells (CSCs), a small population of cancer cells, were revealed to be responsible for tumor initiation, relapse/recurrence, and chemo- or radiotherapy resistance.\(^2\)\(^2\)\(^3\)\(^3\) In HNSCC, several cell surface markers have been reported as CSC marker such as CD44, CD133, ALDH1, and ABCG2.\(^2\)\(^4\)\(^-\)\(^6\) These markers exhibiting high expression usually indicate poor prognosis. Among all these markers, CD44 is the most documented CSC marker presented within HNSCC patient samples.\(^2\)\(^7\)\^-\(^9\) CD44 was found to be a viable target of the Wnt pathway. For the maintenance of stemness of CSCs, Wnt pathway is considered as a main pathway and also accepted as a poor prognostic marker.\(^3\)\(^0\)

Clinical findings stipulate that CSCs exhibit intrinsic property of resistance to therapy. They can vigorously adjust to different environmental conditions, for example, hypoxia and lack of nutrients. Though the fundamental molecular mechanisms are still not well understood, but it was corroborated that CSCs manifest an increased

| Variables | CR (n = 19) (%) | PR (n = 20) (%) | NR (n = 51) (%) | \(\chi^2\) value | \(p\) value |
|-----------|----------------|----------------|----------------|----------------|------------|
| Age (years) | | | | | |
| \(\leq 45\) | 13 (68.4) | 9 (45.0) | 27 (52.9) | 2.26 | 0.322 |
| \(> 45\) | 6 (31.6) | 11 (55.0) | 24 (47.1) | | |
| Gender | | | | | |
| Female | 1 (5.3) | 5 (25.0) | 6 (11.8) | 3.53 | 0.171 |
| Male | 18 (94.7) | 15 (75.0) | 45 (88.2) | | |
| Tobacco | | | | | |
| No | 4 (21.1) | 5 (25.0) | 12 (23.6) | 0.09 | 0.957 |
| Yes | 15 (78.9) | 15 (75.0) | 39 (76.4) | | |
| Alcohol | | | | | |
| No | 16 (84.2) | 11 (55.0) | 26 (51.0) | 6.48 | 0.039* |
| Yes | 3 (15.8) | 9 (45.0) | 25 (49.0) | | |
| Tumor size | | | | | |
| T1 | 1 (5.3) | 3 (15.0) | 2 (3.9) | 13.26 | 0.039* |
| T2 | 5 (26.3) | 3 (15.0) | 8 (15.7) | | |
| T3 | 10 (52.6) | 3 (15.0) | 14 (27.5) | | |
| T4 | 3 (15.8) | 11 (55.0) | 27 (52.9) | | |
| Lymph node status | | | | | |
| N0 | 0 (0.0) | 0 (0.0) | 6 (11.8) | 8.83 | 0.065 |
| N1 | 13 (68.4) | 11 (55.0) | 19 (37.3) | | |
| N2 | 6 (31.6) | 9 (45.0) | 26 (51.0) | | |
| Stage | | | | | |
| III | 13 (68.4) | 6 (30.0) | 16 (31.4) | 8.85 | 0.012* |
| IV | 6 (31.6) | 14 (70.0) | 35 (68.6) | | |
| Grade | | | | | |
| WD | 8 (42.1) | 8 (40.0) | 11 (21.6) | 4.79 | 0.309 |
| MD | 9 (47.4) | 8 (40.0) | 27 (52.9) | | |
| PD | 2 (10.5) | 4 (20.0) | 13 (25.5) | | |

Abbreviations: CR, complete response or complete responder; MD, moderately differentiated; NR, no response or non responder; PD, poorly differentiated; PR, partial response or partial responder; WD, well differentiated.

\(*p < 0.05.\)
scavenging of reactive oxygen species (ROS), enhanced capacity of DNA repair, reduced induction of apoptosis, and enhanced cell survival which play major role in therapy resistance and promotes poor patient’s outcome.\textsuperscript{31,32}

This resistance causes treatment failure in various types of cancer. Therefore, to identify and to target CSCs are indispensable to improve the success rate of treatment.\textsuperscript{33}

Sun et al.\textsuperscript{34} and Lu et al.\textsuperscript{35} have observed that patients exhibiting high expression of CD44 have greater tendency to develop lymph node metastasis, recurrence, and resistance to radiotherapy. In non-Hodgkin's lymphoma and colon cancer, overexpression of CD44 has been correlated with advanced stage and poor survival.\textsuperscript{36} In addition to this, Wang et al.\textsuperscript{37} and Kawano et al.\textsuperscript{38} observed the association of CD44 with lymph node metastasis, tumor volume, and poor survival in HNSCC. In renal cell carcinoma, an association between CD44 and stage, grade, and poor prognosis was observed.\textsuperscript{39} Collectively, these studies stipulated that presence of CD44 in a tumor tissues or cells might play a key role in treatment failure, lymph node metastasis, poor survival, and recurrence.

Along with CD44 and other TNM factors, HPV/p16 positivity is also a known risk factor and an independent prognostic factor. However, this has been excluded from our study because our study is mainly focused on determining the independent predictive significance of CD44. If HPV positivity was taken into account it may confound our results particularly in specimens exhibiting positivity.

### TABLE 3

Identification of predictor of responsiveness to radiotherapy in HNSCC patients using ordinal logistic regression analysis ($n = 90$)

| Predictor | Univariate | Multivariate |
|-----------|------------|--------------|
|           | OR (95% CI) | $p$ value    | OR (95% CI) | $p$ value |
| Age (years) |            |              |            |           |
| ≤45 | Ref | — | — |
| >45 | 0.74 (0.33–1.67) | 0.474 |
| Gender |            |              |            |           |
| Female | Ref | — | — |
| Male | 1.01 (0.31–3.29) | 0.986 |
| Tobacco |            |              |            |           |
| No | Ref | — | — |
| Yes | 1.06 (0.41–2.75) | 0.899 |
| Alcohol |            |              |            |           |
| No | Ref | — | — |
| Yes | 0.39 (0.17–0.93) | 0.033* | 0.24 (0.09–0.65) | 0.005** |
| Tumor size |            |              |            |           |
| T1 + T2 | Ref | — | — |
| T3 + T4 | 0.58 (0.23–1.43) | 0.235 |
| Lymph node |            |              |            |           |
| N0 + N1 | Ref | 0.174 | — | — |
| N2 | 0.57 (0.25–1.28) |
| Stage |            |              |            |           |
| III | Ref | — | — |
| IV | 0.37 (0.16–0.85) | 0.020* | 3.56 (0.96–13.23) | 0.058 |
| Grade |            |              |            |           |
| WD | Ref | — | — |
| MD + PD | 0.43 (0.18–1.02) | 0.055 |
| CD44 |            |              |            |           |
| Low | Ref | — | — |
| High | 0.03 (0.01–0.13) | <0.001*** | 0.01 (0.00–0.07) | <0.001*** |

Note: The mentioned odd ratio is evaluated against reference category, *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$.

Abbreviations: CI, confidence interval; CR, complete response or complete responder; MD, moderately differentiated; NR, no response or non responder; OR, odds ratio; PD, poorly differentiated; PR, partial response or partial responder; Ref, reference category; WD, well differentiated.
for both CD44 and HPV infection. The average age for the diagnosis of HNSCC ranged between 55 and 65 years, whereas in our study, majority of patients were of age <45 years. Sharma et al. have reported that in their study 46.2% of patients were belonged to 31–50 years of age group. Also, in the Indian population, the consumption of tobacco (smokeless and tobacco smoke) and alcohol is quite prevalent, particularly in Northern India people start consuming alcohol and tobacco at a very early age. This explains our finding that in our study majority of patients were of <45 years.

In various previous studies, the role of CD44 and its isoforms especially CD44v has been established in the prognosis and progression of HNSCC. But, current study was mainly focused on the assessment of CD44 expression and no isoform of CD44 has been studied because the involvement of CD44 in response to radiotherapy and OS in HNSCC had not been delineated. Our findings are consistent to the previous studies showing profound clinical importance of CD44. An attempt can be made to understand the clinical relevance of CD44. Our data suggest that patients with high expression of CD44 can increase the number of CSCs that are mainly resistant to radiotherapy which leads to recurrence and tend to have shorter survival. Although, the overall response rate to therapy in our study is low as compared to previous studies. Owing to the fact that in our study, the majority of the patients were of stage IV with N2 lymph node metastasis and T4 tumor size exhibiting more aggressive tumors particularly in younger patients. Additionally, high positivity of CD44 which is also attributed to chemo-radioresistance is also accountable for low overall response rate. Our results corroborate the findings in previous studies establishing that presence of CD44

**FIGURE 2** Two-year overall survival of HNSCC patients using the Kaplan–Meier method. (A) Overall survival showing significant association with tumor size. (B) Overall survival showing significant association with lymph node status. (C) Overall survival showing significant association with stage. (D) Overall survival showing significant association with grade. (E) Overall survival showing significant association with CD44 expression. (F) Overall survival showing no significant association with treatment response.
was correlated with treatment failure, lymph node metastasis, advanced stage, tumor size, grade, recurrence, and poor survival. An evident aspect of current study was that CD44 may be an indicator of poor prognosis in advanced stage patients of HNSCC. Therefore, based on our findings, we can propose that it may be necessary to employ CD44 as the viable target in order to determine the effective treatment modalities and to gather all the relevant information which can be transcribed into patient benefit.

In conclusion, our study demonstrated that high CD44 expression is the predictive marker for the treatment and OS which contributes to treatment failure, poor survival, and recurrence. However, further exploration is warranted.

### Table 4: Time-dependent/independent predictors of survival using univariate and multivariate Cox regression analyses (n = 90)

| Predictor      | Univariate | Multivariate |
|---------------|------------|--------------|
|               | OR (95% CI) | p value      | OR (95% CI) | p value      |
| Age (years)   |            |              |              |              |
| ≤45           | Ref        |              | Ref          |              |
| >45           | 0.91 (0.60–1.38) | 0.667 | 0.68 (0.41–1.12) | 0.126 |
| Gender        |            |              |              |              |
| Female        | Ref        |              | Ref          |              |
| Male          | 1.13 (0.62–2.08) | 0.690 | 1.22 (0.60–2.48) | 0.578 |
| Tobacco       |            |              |              |              |
| No            | Ref        |              | Ref          |              |
| Yes           | 0.95 (0.59–1.56) | 0.851 | 0.83 (0.49–1.42) | 0.499 |
| Alcohol       |            |              |              |              |
| No            | Ref        |              | Ref          |              |
| Yes           | 1.41 (0.93–2.15) | 0.108 | 1.67 (1.00–2.78) | 0.049 |
| Tumor size    |            |              |              |              |
| T1 + T2       | Ref        |              | Ref          |              |
| T3 + T4       | 1.37 (0.84–2.21) | 0.205 | 1.89 (0.93–3.84) | 0.076 |
| Lymph node    |            |              |              |              |
| N0            | Ref        |              | Ref          |              |
| N1 + N2       | 1.58 (0.69–3.62) | 0.280 | 5.93 (2.13–16.57) | 0.001** |
| Stage         |            |              |              |              |
| III           | Ref        |              | Ref          |              |
| IV            | 1.48 (0.97–2.27) | 0.069 | 0.64 (0.31–1.31) | 0.224 |
| Grade         |            |              |              |              |
| WD            | Ref        |              | Ref          |              |
| MD + PD       | 1.98 (1.26–3.12) | 0.003** | 2.89 (1.65–5.05) | <0.001*** |
| CD44          |            |              |              |              |
| Low           | Ref        |              | Ref          |              |
| High          | 1.44 (0.85–2.44) | 0.179 | 3.65 (1.57–8.46) | 0.003** |
| Response      |            |              |              |              |
| CR + PR       | Ref        |              | Ref          |              |
| NR            | 1.22 (0.80–1.85) | 0.358 | 0.99 (0.61–1.62) | 0.995 |
| Recurrence    |            |              |              |              |
| No            | Ref        |              | Ref          |              |
| Yes           | 0.79 (0.52–1.21) | 0.281 | 0.22 (0.12–0.41) | <0.001*** |

Note: The mentioned odd ratio is evaluated against reference category, *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Abbreviations: CI, confidence interval; CR, complete response or complete responder; MD, moderately differentiated; NR, no response or non responder; OR, odds ratio; PD, poorly differentiated; PR, partial response or partial responder; Ref, reference category; WD, well differentiated.
to understand the mechanism of CD44 including all other isoforms of CD44. The ratio of CD44 along with other markers of CSCs could also be evaluated in forthcoming studies to understand the mechanism of CSCs in treatment failure which will further help clinicians to devise an effective anticancer therapy of improved efficacy.

ACKNOWLEDGMENTS
The authors are thankful to the Vice Chancellor of KGMU, Lucknow, India and the Director of CSIR-CDRI, Lucknow, India for providing the facility and infrastructure. The authors are also thankful to all the patients for their participation in the study.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR’S CONTRIBUTION
Conception and design: Madanlal Brahma Bhatt and Parul Dubey. Analysis and interpretation of data: Madanlal Brahma Bhatt and Parul Dubey. Drafting, review, and/or revision of the manuscript: Madanlal Brahma Bhatt, Parul Dubey, Smrati Bhadauria, Rajeev Gupta, Anupam Mishra, and Vijay Kumar. Final approval: Madanlal Brahma Bhatt and Smrati Bhadauria.

ETHICS STATEMENT
The Institutional Ethics Committee has approved the study protocol, which follows the Declaration of Helsinki.

DATA AVAILABILITY STATEMENT
Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

ORCID
Madan Lal Brahma Bhatt https://orcid.org/0000-0003-4832-6715

REFERENCES
1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Allegra E, Trapasso S. Cancer stem cells in head and neck cancer. Onco Targets Ther. 2012;5:375-383.
3. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck. 2005;27(10):843-850.
4. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4–5):309-316.
5. Zhang P, Zhang Y, Mao L, et al. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett. 2009;277(2):227-234.
6. Liebertz DJ, Lechner MG, Masood R, et al. Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. Head and Neck Oncology. 2010;2:5.
7. McCullough MJ, Prasad G, Farah CS. Oral mucosal malignancy and potentially malignant lesions: an update on the epidemiology, risk factors, diagnosis and management. Aust Dent J. 2010;55:61-65.
8. Harper LJ, Costea DE, Gammon L, et al. Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer. 2010;10:166.
9. Mahal BA, Catalano PJ, Haddad RI, et al. Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the United States. Cancer Epidemiol Biomark Prev. 2019;28:1660-1667.
10. Ribeiro KB, Levi JE, Pawlita M, et al. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol. 2011;40:489-502.
11. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
12. Szafarowski T, Szczepanski MJ. Cancer stem cells in head and neck squamous cell carcinoma. Otalaryngologia Polska. 2014;68:105-111.
13. Han J, Fujisawa T, Husain SR, et al. Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma. BMC Cancer. 2014;14:173.
14. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. PNAS. 2007;104:973-978.
15. Gao L, Yan L, Lin B, et al. Enhancive effects of Lewis y antigen on CD44-mediated adhesion and spreading of human ovarian cancer cell line RMG-I. J Exp Clin Cancer Res. 2011;30:15.
16. Hanagiri T, Shinohara S, Takenaka M, et al. Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma. Tumour Biol. 2012;33(6):2135-2141.
17. Lessard J, Sauvageaun G. Bmi-1 determines the proliferative capacity of normal and leukemic stem cells. Nature. 2003;423(6937):255-260.
18. Park IK, Morrison SJ, Clarke MF. Bmi-1, stem cells, and senescence regulation. J Clin Invest. 2004;113(2):175-179.
19. Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-1474.
20. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
21. Collina F, Di Bonito M, Li Bergolis V, et al. Prognostic value of cancer stem cells markers in triple-negative breast cancer. BioMed Res Int. 2015;2015:158682.
22. Lobo NA, Shimono Y, Qian D, et al. The biology of cancer stem cells. Ann Rev Cell Dev Biol. 2007;23:675-699.
23. Bomken S, Fišer K, Heidenreich O, et al. Understanding the cancer stem cell. Br J Canc. 2010;103(4):439-445.
24. Chioiu S-H, Yu C-C, Huang C-Y, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and
high grade oral squamous cell carcinoma. Clin Canc Res. 2008;14(13):4085-4095.

25. Yu CC, Chang YC. Enhancement of cancer stem-like and epithelial-mesenchymal trans-differentiation property in oral epithelial cells with long-term nicotine exposure: reversal by targeting SNAIL. Toxicol Appl Pharmacol. 2013;266(3):459-469.

26. Chen Y-S, Wu M-J, Huang C-Y, et al. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS One. 2011;6(11):e28053.

27. Trapasso S, Allegra E. Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biol Targets Ther. 2012;6:379-383.

28. Joshua B, Kaplan MJ, Dowec I, et al. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck. 2012;34(1):42-49.

29. Chikamatsu K, Takahashi G, Sakakura K, et al. Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck. 2011;33(2):208-215.

30. Kwong LN, Dove WF. APC and its modifiers in colon cancer. Adv Exp Med Biol. 2009;656:85-106.

31. Peitzsch C, Kurth I, Ebert N, et al. Cancer stem cells in radiation response: current views and future perspectives in radiation oncology. Int J Radiat Biol. 2019;2019:1-42.

32. Krause M, Dubrovskia A, Linge A, et al. Cancer stem cells: radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev. 2017;109:63-73.

33. Croker AK, Allan AL. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHpositiveCD44+ human breast cancer cells. Breast Cancer Res Treat. 2012;133:75-87.

34. Sun B, Zhao S, Zhou C, et al. Detection of PD4, CD44, PCNA protein and its clinical significance in human laryngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010;24:817-819. Chinese.

35. Lu S, Tian J, Lv Z, et al. The probable role of tumor stem cells for lymph node metastasis in supraglottic carcinoma. Pathol Oncol Res. 2011;17:33-38.

36. Kuhn S, Koch M, Nübel T, et al. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res. 2007;5:553-567.

37. Wang SJ, Wreesmann VB, Bourguignon LY. Association of CD44 v3 containing isoforms in tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. Head Neck. 2007;29:550-558.

38. Kawano T, Nakamura Y, Yanoma S, et al. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer. Auris Nasus Larynx. 2004;31:35-41.

39. Li N, Tsuji M, Kanda K, et al. Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma. BJU Int. 2000;85(4):514-518.

40. Vigneswaran N, Williams MD. Epidemiological trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am. 2014;26(2):123-141.

41. Sharma M, Madan M, Manjari M, et al. Prevalence of head and neck squamous cell carcinoma (HNSCC) in our population: the clinic-pathological and morphological description of 19 cases. Int J Adv Res. 2015;3(1):827-833.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Dubey P, Gupta R, Mishra A, Kumar V, Bhadauria S, Bhatt MLB. Evaluation of correlation between CD44, radiotherapy response, and survival rate in patients with advanced stage of head and neck squamous cell carcinoma (HNSCC). Cancer Med. 2022;11:1937–1947. doi:10.1002/cam.4497